Eventide Asset Management’s Acceleron Pharma XLRN Stock Holding History

Eventide Asset Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-142,900	Closed	-$19.4M	–	168
2021 Q1	$19.4M	Hold	142,900	–	–	0.29%	94
2020 Q4	$18.3M	Hold	142,900	–	–	0.28%	93
2020 Q3	$16.1M	Hold	142,900	–	–	0.31%	88
2020 Q2	$13.6M	Hold	142,900	–	–	0.3%	85
2020 Q1	$12.8M	Buy	+142,900	New	+$11.1M	0.42%	72
2019 Q2	–	Sell	-128,900	Closed	-$6M	–	137
2019 Q1	$6M	Hold	128,900	–	–	0.21%	88
2018 Q4	$5.61M	Hold	128,900	–	–	0.25%	86
2018 Q3	$7.38M	Sell	128,900 -401,000	-76%	-$19.7M	0.27%	88
2018 Q2	$25.7M	Hold	529,900	–	–	1.07%	38
2018 Q1	$20.7M	Sell	529,900 -124,000	-19%	-$5.27M	0.97%	38
2017 Q4	$27.8M	Hold	653,900	–	–	1.45%	28
2017 Q3	$24.4M	Hold	653,900	–	–	1.38%	29
2017 Q2	$19.9M	Hold	653,900	–	–	1.24%	36
2017 Q1	$17.3M	Buy	653,900 +225,000	+52%	+$5.93M	1.15%	39
2016 Q4	$10.9M	Hold	428,900	–	–	0.71%	49
2016 Q3	$15.5M	Hold	428,900	–	–	0.95%	39
2016 Q2	$14.6M	Buy	428,900 +5,400	+1%	+$176K	0.89%	43
2016 Q1	$11.2M	Buy	423,500 +300,000	+243%	+$8.72M	0.62%	54
2015 Q4	$6.02M	Buy	123,500 +36,400	+42%	+$1.31M	0.3%	79
2015 Q3	$2.17M	Hold	87,100	–	–	0.13%	98
2015 Q2	$2.76M	Hold	87,100	–	–	0.15%	91
2015 Q1	$3.31M	Buy	87,100 +25,000	+40%	+$994K	0.25%	82
2014 Q4	$2.42M	Hold	62,100	–	–	0.26%	75
2014 Q3	$1.88M	Hold	62,100	–	–	0.26%	74
2014 Q2	$2.11M	Buy	+62,100	New	+$2.08M	0.29%	73

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Eventide Asset Management's XLRN Position: Q2 2021 in Review

Eventide Asset Management sold out of Acceleron Pharma (XLRN) in Q2 2021, closing a stake of 142,900 shares — an estimated $19.4M sold.

Eventide Asset Management first reported a position in XLRN in Q2 2014 and held it in 25 quarters. The position peaked at $27.8M in Q4 2017. 271 funds tracked by Wall St. Rank hold XLRN as of Q2 2021.

Eventide Asset Management reported no remaining Acceleron Pharma position as of Q2 2021 after selling out during the quarter.
Eventide Asset Management sold 142,900 Acceleron Pharma shares in Q2 2021, an estimated $19.4M.
Eventide Asset Management first reported a position in Acceleron Pharma in Q2 2014 and held it in 25 quarters.
Eventide Asset Management's Acceleron Pharma position peaked at $27.8M in Q4 2017.
271 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2021.

Based on Eventide Asset Management's 13F filing for Q2 2021, filed 16 Aug 2021.